Aim: To identify factors that may be predictors of the outcome of a detoxification treatment in medication-overuse headache.

Methods: Consecutive patients entering a detoxification program in six centres in Europe and Latin America were evaluated and followed up for 6 months. We evaluated anxious and depressive symptomatology (though patients with severe psychiatric comorbidity were excluded), quality of life, headache-related disability, headache characteristics, and prophylaxis upon discharge.

Results: Of the 492 patients who completed the six-month follow up, 407 ceased overuse following the detoxification (non overusers), another 23 ceased overuse following detoxification but relapsed during the follow-up. In the 407 non-overusers, headache acquired an episodic pattern in 287 subjects (responders). At the multivariate analyses, lower depression scores (odds ratio = 0.891; p = 0.001) predicted ceasing overuse. The primary headache diagnosis - migraine with respect to tension-type headache (odds ratio = 0.224; p = 0.001) or migraine plus tension-type headache (odds ratio = 0.467; p = 0.002) - and the preventive treatment with flunarizine (compared to no such treatment) (odds ratio = 0.891; p = 0.001) predicted being a responder. A longer duration of chronic headache (odds ratio = 1.053; p = 0.032) predicted relapse into overuse. Quality of life and disability were not associated with any of the outcomes.

Conclusions: Though exploratory in nature, these findings point to specific factors that are associated with a positive outcome of medication-overuse headache management, while identifying others that may be associated with a negative outcome. Evaluation of the presence/absence of these factors may help to optimize the management of this challenging groups of chronic headache sufferers.

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102418783317DOI Listing

Publication Analysis

Top Keywords

headache odds
12
headache
9
predictors outcome
8
outcome detoxification
8
medication-overuse headache
8
quality life
8
ceased overuse
8
overuse detoxification
8
odds ratio = 0891
8
ratio = 0891 p = 0001
8

Similar Publications

Background: Lecanemab, a novel monoclonal antibody targeting amyloid-β, has shown promise in treating Alzheimer's disease. Comprehensive post-marketing safety data analysis is crucial to understand its real-world risk profile.

Objective: This study aimed to evaluate the safety profile of lecanemab using data from the FDA Adverse Event Reporting System (FAERS), with a focus on nervous system disorders and amyloid-related imaging abnormalities.

View Article and Find Full Text PDF

Neuropathic pain characteristics in patients with pain-related temporomandibular disorders.

J Oral Facial Pain Headache

June 2024

Department of Orofacial Pain & Dysfunction, Academic Centre for Dentistry Amsterdam (ACTA), 1081 LA Amsterdam, The Netherlands.

In orofacial pain patients, pain-related temporomandibular disorders (TMD) and neuropathic pain (NP) can both be present. The aim of this cross-sectional study was to examine whether in patients with orofacial pain, associations can be found between (subdiagnoses of) pain-related TMD and NP. Participants were asked to fill in the questionnaires of the Diagnostic Criteria for TMD (DC/TMD) and a screening questionnaire for NP, the Douleur Neuropathique 4 (DN4).

View Article and Find Full Text PDF

The simultaneous occurrence of primary headaches and temporomandibular disorders can pose a challenge in determining the best clinical management of patients. Therefore, we aimed to summarize evidence regarding the risk and prevalence of temporomandibular disorders (TMDs) in migraine and tension-type headaches (TTH) patients. Cross-sectional studies published in English comparing the presence of TMDs in adults with TTH or migraine to subjects without headaches were included, International Classification of Orofacial Pain, Diagnostic Criteria for Temporomandibular Disorders or Research Diagnostic Criteria for Temporomandibular Disorders, and large epidemiological studies (sensitive diagnostic criteria (SDC)).

View Article and Find Full Text PDF

To evaluate the association between definitive sleep bruxism and primary headaches and to analyze other variables that may also be associated with definitive sleep bruxism. A descriptive study was carried out with a sample of adults with a medical indication for polysomnography in Florianópolis, Brazil. Data were collected in three phases: questionnaires, physical examinations and polysomnography.

View Article and Find Full Text PDF

Calcitonin gene-related peptide (CGRP) monoclonal antibodies in the treatment of episodic and chronic migraine was invetigated. A comprehensive literature search was conducted in Ovid Medline, Web of Science and Embase databases from their inception until April 2024 for randomized controlled trials comparing CGRP monoclonal antibodies with placebo or other active treatments in adults with episodic or chronic migraine. The primary outcome assessed was the incidence of hypertension, and secondary outcomes were tolerability, acceptability and adverse events.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!